Skip to contentpdufa.bio

RAP-641 (α6β4 nAChR)

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

RAP-641 (α6β4 nAChR) is a Rapport Therapeutics, Inc. program in chronic pain and migraine. Its next catalyst is a Readout in Q4 2027.

RAPP catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indication under review: Chronic pain and migraine. Sponsor: Rapport Therapeutics, Inc. (RAPP). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Q4 2027RAPP

Specialist biotech funds holding RAPP, 13F for the quarter ended September 30, 2026

FundSharesValue at quarter endFiling
Cormorant Asset Management2,457,521$82.6 millionfiled November 16, 2026
Baker Bros. Advisors1,547,090$52.0 millionfiled November 16, 2026
Perceptive Advisors724,342$24.3 millionfiled November 16, 2026

13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.

Questions

When is RAP-641 (α6β4 nAChR)'s next FDA decision or readout?

The next tracked catalyst for RAP-641 (α6β4 nAChR) is a Readout in Q4 2027.

What happened at RAP-641 (α6β4 nAChR)'s most recent FDA decision?

No FDA decision for RAP-641 (α6β4 nAChR) is in our archive yet.

What is RAP-641 (α6β4 nAChR) used for?

In our records RAP-641 (α6β4 nAChR) is under review or in development for Chronic pain and migraine.

Who makes RAP-641 (α6β4 nAChR)?

Rapport Therapeutics, Inc. (RAPP).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.